GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Margin of Safety % (DCF FCF Based)

Akero Therapeutics (STU:0K4) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 11, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Akero Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Akero Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Akero Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Akero Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akero Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


;
;

Akero Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Akero Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Margin of Safety % (DCF FCF Based)
Comparable Companies
RYTM RARE SLNO SWTX CRNX CRSP IMVT SRRK MRUS ACLX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AKRO:USA
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Website
https://www.akerotx.com
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines